Journalist Hunt

JournalistsPricingBlogs
LoginSign up

George Vlachogiannis - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock George Vlachogiannis's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
George Vlachogiannis

George Vlachogiannis

Verified

Managing Editor, Cancer Control, SAGE Publishing

London

Beats

Primary beats

Health

Secondary beats

CultureThe ArtsSo Much MoreWellnessArtsLeisureSearch Engine OptimizationLocal PoliticsCelebrity InterviewsHealthcareHealthMedical ResearchProfileSolo TravelPhilosophyCulinaryInternationalFitnessDisability

Final Covers

HEALTH SCIENCE

Doesn’t Cover

I'm open to covering any topic.

Journalist Type

-

Seniority Positions

-

Industries

Medium Formats

-

Content

Total articles 1

  • Metastatic colorectal cancer (mCRC) patient derived organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs - European Journal of Surgical Oncology

    By Yann Jamin, Khurum Khan, Somaieh Hedayat, George Vlachogiannis| EJSO - European Journal of Surgical Oncology Verified To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Background: Regorafenib demonstrated efficacy in pre-treated mCRC patients by inhibiting tumour vasculature. Limited clinical benefit in unselected patient populations highlights the unmet need for better patient selection and identification of mechanisms of action.

    By Yann Jamin, Khurum Khan, Somaieh Hedayat, George Vlachogiannis · EJSO - European Journal of Surgical Oncology

    Nov. 23, 2017

  • Metastatic colorectal cancer (mCRC) patient derived organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs - European Journal of Surgical Oncology

    By Yann Jamin, Khurum Khan, Somaieh Hedayat, George Vlachogiannis| EJSO - European Journal of Surgical Oncology Verified To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Background: Regorafenib demonstrated efficacy in pre-treated mCRC patients by inhibiting tumour vasculature. Limited clinical benefit in unselected patient populations highlights the unmet need for better patient selection and identification of mechanisms of action.

    By Yann Jamin, Khurum Khan, Somaieh Hedayat, George Vlachogiannis · EJSO - European Journal of Surgical Oncology

    Nov. 23, 2017

As seen in

Ejso - European Journal Of Surgical Oncology,Sage Publishing

Company Info

SAGE Publishing

Thousand Oaks, California, United States

+1 800-818-7243